In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Bid For Genentech, How High Can Roche Go?

Executive Summary

Roche's effort to clinch a buy-out of Genentech has moved to a new, critical stage of negotiations. But just how much can Roche afford to pay for the top-of-the-line biotech, which comes with A-list scientific talent, an extensive pipeline heavily weighted in the lucrative arena of oncology, and a price tag to match?

You may also be interested in...



Roche/Genentech: A Case Study For Future Hostile Offers

It's almost a certainty that five years from now gurus at top-notch B-schools will include the Roche/Genentech saga as a critical case-study in how-or how not-to acquire a partner. They will laud--or criticize--Severin Schwan, Roche's new CEO, for his chutzpah, pending the outcome of the ensuing weeks.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008

Highlights from the Q3 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was more than twice that of Q2 with 105 deals bringing in over $4.4 billion, but not one IPO to be found. M&A dollars also nearly doubled to $23 billion in the third quarter--versus the previous three months--and of the 26 transactions with known values, more than half were over $100 million. Alliances saw activity focused primarily in two areas: drug delivery and large molecules, each category with 16 deals apiece. Total potential deal value (for the 43 alliances with known values) reached $4.5 billion, over one and a half times that of the previous quarter.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008

Highlights from the Q3 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was more than twice that of Q2 with 105 deals bringing in over $4.4 billion, but not one IPO to be found. M&A dollars also nearly doubled to $23 billion in the third quarter--versus the previous three months--and of the 26 transactions with known values, more than half were over $100 million. Alliances saw activity focused primarily in two areas: drug delivery and large molecules, each category with 16 deals apiece. Total potential deal value (for the 43 alliances with known values) reached $4.5 billion, over one and a half times that of the previous quarter.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

CO200859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel